Last reviewed · How we verify

NCT06603753

Role of Serum (B/A) Ratio Compared to (TSB) for Early Prediction of Bilirubin-induced Neurological Dysfunction (BIND).

Not yet recruiting Last updated 19 September 2024
What this trial tests

trial in Hyperbilirubinemia, Neonatal in 80 participants. Not yet recruiting.

Timeline
1 January 2025
Primary endpoint
1 January 2026
1 July 2026

Quick facts

Lead sponsoralaa aboelhassan mohamed aboelhassan
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment80
Start date1 January 2025
Primary completion1 January 2026
Estimated completion1 July 2026

Conditions studied

Sponsor

alaa aboelhassan mohamed aboelhassan

Who can join

Adults 1 Day to 28 Days, any sex, with Hyperbilirubinemia, Neonatal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate serum bilirubin/albumin (B/A) ratio compared to total serum bilirubin (TSB) for early prediction of bilirubin-induced neurological dysfunction (BIND).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hyperbilirubinemia, Neonatal

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06603753.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing